Viehbacher: Sanofi, Genzyme have mutually beneficial qualities

04/8/2011 | Boston Globe (tiered subscription model), The

Sanofi-Aventis CEO Christopher A. Viehbacher said Genzyme's focus on patients and open partnerships are some of the characteristics that could benefit Sanofi, while the latter's global sales force and other resources could help Genzyme. Although there still are many business decisions to make, Viehbacher said, Sanofi plans to support the development of Genzyme's three drug candidates, including a treatment for Niemann-Pick disease, that have been halted after the firm focused its attention addressing manufacturing issues.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC